Skip to main content

Dr. Craig A. Rohan, MD

Dermatology (Dermatology Physician)

  • Medicare participating

At a glance

Years since graduation
25
In the NPI registry since
2006
Medicare patients seen, 2024
329

Licensed in California since 2009, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2001Medical school: University of Colorado School of Medicine, Denver
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Dermatology Physician primary
    CA license C53682 (first issued 2009; current)
  • Pediatric Dermatology Physician
    CA license C53682 (first issued 2009; current)
  • Pediatrics Physician
    CA license C53682 (first issued 2009; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Dermatology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
329
Services billed
1,416
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Destruction of precancer skin growth, 2-14 growths21045
Established patient office or other outpatient visit, 30-39 minutes182108
Established patient office or other outpatient visit, 20-29 minutes12290
Destruction of precancer skin growth, 1 growth6454
Established patient office or other outpatient visit, 10-19 minutes6252
New patient office or other outpatient visit, 30-44 minutes4747
New patient office or other outpatient visit, 45-59 minutes3737
Destruction of skin growth, 1-14 growths3329
Biopsy of related skin growth, first growth2623
New patient office or other outpatient visit, 15-29 minutes1818

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 17 payments worth $8,017 in total to this clinician.

By company
UCB SA$7,014
Novartis Pharmaceuticals Corporation$1,003
By type
Compensation for services other than consulting (speaking, faculty)$5,482
Travel and Lodging$2,010
Food and Beverage$525

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$3,295
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$1,170
Nov 22, 2025UCB SA
Nov 22, 2025
Travel and Lodging
Bimzelx · Immunology · travel to Toronto, Canada · in-kind
$705
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$565
Sep 26, 2025Novartis Pharmaceuticals Corporation
Sep 26, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
$446
Nov 22, 2025UCB SA
Nov 22, 2025
Travel and Lodging
Bimzelx · Immunology · travel to Toronto, Canada · in-kind
$331
Nov 22, 2025UCB SA
Nov 22, 2025
Travel and Lodging
Bimzelx · Immunology · travel to Toronto, Canada · in-kind
$330
Sep 26, 2025Novartis Pharmaceuticals Corporation
Sep 26, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
$198
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$169
Apr 3, 2025UCB SA
Apr 3, 2025
Compensation for services other than consulting (speaking, faculty)$164
All 11 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Nov 22, 2025UCB SA
Nov 22, 2025
Travel and Lodging
Bimzelx · Immunology · travel to Toronto, Canada · in-kind
$705
Nov 22, 2025UCB SA
Nov 22, 2025
Travel and Lodging
Bimzelx · Immunology · travel to Toronto, Canada · in-kind
$331
Nov 22, 2025UCB SA
Nov 22, 2025
Travel and Lodging
Bimzelx · Immunology · travel to Toronto, Canada · in-kind
$330
Sep 26, 2025Novartis Pharmaceuticals Corporation
Sep 26, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
$446
Sep 26, 2025Novartis Pharmaceuticals Corporation
Sep 26, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
$198
Apr 3, 2025UCB SA
Apr 3, 2025
Compensation for services other than consulting (speaking, faculty)$164
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$3,295
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$1,170
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$565
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$169
Feb 17, 2025UCB SA
Feb 17, 2025
Compensation for services other than consulting (speaking, faculty)$120

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Ohio →

Industry-funded research

Named as a principal investigator on 21 industry-funded studies in 2025, from 10 companies. The companies reported $387,652 in research payments for these studies, mostly to the institutions running them.

  • TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
    Takeda Pharmaceuticals U.S.A., Inc.
  • A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients wi…
    Novartis Pharmaceuticals Corporation
  • A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
    E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06136741
  • A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized …
    Janssen Research & Development, LLC
  • Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
    Organon Llc · Completed · NCT05172726
  • A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
    Janssen Research & Development, LLC
  • A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Contro…
    Amgen Inc.
  • M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
    AbbVie Inc.
  • A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 60 weeks of treatment with a withdrawal and retreatment period
    Takeda Pharmaceuticals U.S.A., Inc.
  • Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
    AbbVie Inc. · Completed · NCT05969223

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Wright Patterson Afb

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 6, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1366414591. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.